Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Richard S P Huang¹, Derek Smith¹, Catherine H Le¹+25

• ¹From Roche Molecular Solutions, Pleasanton, California (Dr Huang, Mr Smith, Dr Le, Mr Liu, Dr Ordinario, Dr Manohar, Mr Lee, Mr Rajamani, Mr Truong, Dr Jing Li, Ms Choi, Dr Jingchuan Li, Dr Pati, Dr Hanlon Newell, Mr Pate, and Dr Menzl); Institute of Pathology, University Hospital Basel, Basel, Switzerland (Dr Bubendorf); Institute for Pathology, University Hospital, Cologne, Germany (Dr Buettner); the Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Foresterhill, Aberdeen, United Kingdom (Dr Kerr); Laboratorio de Dianas Terapeuticas, HM Hospitales, Spain (Dr Lopez-Rios); Center of Predictive Molecular Medicine, CeSIMeT, University of Chieti-Pescara, Italy (Dr Marchetti); Pfizer Oncology, International Developed Markets, Berlin, Germany (Dr Marondel); the Department of Histopathology, Royal Brompton and Harefield Hospitals, and National Heart and Lung Division, Imperial College, London, United Kingdom (Dr Nicholson); the Pathology Department, Istanbul University, Cerrahpassa Medical Faculty, Istanbul, Turkey (Dr Öz); CORE, Antwerp University, and the Department of Pathology, Antwerp University Hospital, Antwerp, Belgium (Dr Pauwels); the Department of Biopathology, Centre Jean Perrin & INSERM U240 IMoST and Université Clermont Auvergne, Clermont-Ferrand, France (Dr Penault-Llorca); Operative Unit of Pathology, AUSL della Romagna, Hospital S. Maria delle Croci, Ravenna, Italy (Dr Rossi); and the Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands (Dr Thunnissen).